Share

Rapid Nutrition PLC Stocks

14.5Last Updated 16.03.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

€ 7.95M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
14.5
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Rapid Nutrition PLC, a natural healthcare company, researches, develops, and produces a rage of science-based health and wellness products in the United Kingdom, Australia, Asia, the United States, and internationally. The company offers organic and natural scientific-based health food supplements under the SystemLS and Leisa's Secret brands. It also provides oral anti-viral therapy products to combat flu and common cold under the Azurene brand name. The company was founded in 2001 and is based in London, the United Kingdom.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7

The average target price of ALRPD.PA is 25 and suggests 75% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks